These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 24114957)

  • 1. Phase I design for completely or partially ordered treatment schedules.
    Wages NA; O'Quigley J; Conaway MR
    Stat Med; 2014 Feb; 33(4):569-79. PubMed ID: 24114957
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A comparison of phase I dose-finding designs in clinical trials with monotonicity assumption violation.
    Abbas R; Rossoni C; Jaki T; Paoletti X; Mozgunov P
    Clin Trials; 2020 Oct; 17(5):522-534. PubMed ID: 32631095
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dose-finding design for multi-drug combinations.
    Wages NA; Conaway MR; O'Quigley J
    Clin Trials; 2011 Aug; 8(4):380-9. PubMed ID: 21652689
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Shift models for dose-finding in partially ordered groups.
    Horton BJ; Wages NA; Conaway MR
    Clin Trials; 2019 Feb; 16(1):32-40. PubMed ID: 30309262
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Seamless Phase I/II Adaptive Design for Oncology Trials of Molecularly Targeted Agents.
    Wages NA; Tait C
    J Biopharm Stat; 2015; 25(5):903-20. PubMed ID: 24904956
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Continual reassessment method for partial ordering.
    Wages NA; Conaway MR; O'Quigley J
    Biometrics; 2011 Dec; 67(4):1555-63. PubMed ID: 21361888
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Isotonic designs for phase I trials in partially ordered groups.
    Conaway M
    Clin Trials; 2017 Oct; 14(5):491-498. PubMed ID: 28776422
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of irrational dose assignment definitions using the continual reassessment method.
    Wages NA; Bagley E
    Clin Trials; 2019 Dec; 16(6):665-672. PubMed ID: 31547691
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identifying a maximum tolerated contour in two-dimensional dose finding.
    Wages NA
    Stat Med; 2017 Jan; 36(2):242-253. PubMed ID: 26910586
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dose finding with continuous outcome in phase I oncology trials.
    Wang Y; Ivanova A
    Pharm Stat; 2015; 14(2):102-7. PubMed ID: 25408518
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Extended model-based designs for more complex dose-finding studies.
    O'Quigley J; Conaway M
    Stat Med; 2011 Jul; 30(17):2062-9. PubMed ID: 21351287
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Using the time-to-event continual reassessment method in the presence of partial orders.
    Wages NA; Conaway MR; O'Quigley J
    Stat Med; 2013 Jan; 32(1):131-41. PubMed ID: 22806898
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Specifications of a continual reassessment method design for phase I trials of combined drugs.
    Wages NA; Conaway MR
    Pharm Stat; 2013; 12(4):217-24. PubMed ID: 23729323
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modeling adverse event counts in phase I clinical trials of a cytotoxic agent.
    Muenz DG; Braun TM; Taylor JM
    Clin Trials; 2018 Aug; 15(4):386-397. PubMed ID: 29779418
    [TBL] [Abstract][Full Text] [Related]  

  • 15. How to design a dose-finding study using the continual reassessment method.
    Wheeler GM; Mander AP; Bedding A; Brock K; Cornelius V; Grieve AP; Jaki T; Love SB; Odondi L; Weir CJ; Yap C; Bond SJ
    BMC Med Res Methodol; 2019 Jan; 19(1):18. PubMed ID: 30658575
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modified toxicity probability interval design: a safer and more reliable method than the 3 + 3 design for practical phase I trials.
    Ji Y; Wang SJ
    J Clin Oncol; 2013 May; 31(14):1785-91. PubMed ID: 23569307
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A design for phase I trials in completely or partially ordered groups.
    Conaway MR
    Stat Med; 2017 Jul; 36(15):2323-2332. PubMed ID: 28384843
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I/II adaptive design for drug combination oncology trials.
    Wages NA; Conaway MR
    Stat Med; 2014 May; 33(12):1990-2003. PubMed ID: 24470329
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An adaptive multi-stage phase I dose-finding design incorporating continuous efficacy and toxicity data from multiple treatment cycles.
    Du Y; Yin J; Sargent DJ; Mandrekar SJ
    J Biopharm Stat; 2019; 29(2):271-286. PubMed ID: 30403559
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dose-finding design using mixed-effect proportional odds model for longitudinal graded toxicity data in phase I oncology clinical trials.
    Doussau A; Thiébaut R; Paoletti X
    Stat Med; 2013 Dec; 32(30):5430-47. PubMed ID: 24018535
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.